![]() |
市場調查報告書
商品編碼
1892828
導絲市場機會、成長促進因素、產業趨勢分析及預測(2025-2034年)Guidewires Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
||||||
2024 年全球導絲市場價值為 13 億美元,預計到 2034 年將以 5.7% 的複合年成長率成長至 23 億美元。

市場擴張的促進因素包括老年人口的成長、生活型態相關疾病盛行率的上升、已開發國家有利的健保報銷政策以及心血管疾病發生率的增加。導絲設計的技術進步,例如智慧導絲和生物可吸收導絲,進一步推動了導絲的應用。醫療保健從傳統開放性手術轉變為微創手術(包括經皮冠狀動脈介入治療 (PCI)、神經血管介入治療和血管內治療)的轉變,顯著促進了市場成長。這些手術可以減少創傷、縮短住院時間並加速復原。導絲在幫助臨床醫生精準操控複雜血管結構、提高手術成功率和改善患者預後方面發揮著至關重要的作用。新興經濟體醫療基礎設施的擴建也為導絲的應用創造了新的機會。
| 市場範圍 | |
|---|---|
| 起始年份 | 2024 |
| 預測年份 | 2025-2034 |
| 起始值 | 13億美元 |
| 預測值 | 23億美元 |
| 複合年成長率 | 5.7% |
2024 年,鎳鈦諾細分市場佔 46.3% 的市佔率。由於有利的報銷政策和優異的材料性能(包括形狀記憶和超彈性),預計該細分市場將繼續成長,這些性能為在心血管、外周和神經血管手術中穿過迂曲血管提供了增強的柔韌性和抗扭結性。
2024 年,塗層導絲佔了 89.3% 的市佔率。採用親水、抗血栓、疏水和矽基技術的塗層導絲因其臨床療效和在介入手術中的廣泛應用而備受青睞。
2024年,北美導絲市佔率將達到37.7%。該地區受益於先進的醫療基礎設施、高手術量、微創介入治療的快速普及以及持續的技術創新。心血管疾病、周邊動脈疾病、神經血管疾病和泌尿系統疾病的高發生率推動了導絲在診斷和治療應用方面的需求。
The Global Guidewires Market was valued at USD 1.3 billion in 2024 and is estimated to grow at a CAGR of 5.7% to reach USD 2.3 billion by 2034.

Market expansion is driven by the rising elderly population, increasing prevalence of lifestyle-related disorders, supportive reimbursement policies in developed countries, and growing rates of cardiovascular diseases. Technological advancements in guidewire design, such as smart and bioresorbable models, are further fueling adoption. The shift in healthcare from traditional open surgeries to minimally invasive procedures, including Percutaneous Coronary Intervention (PCI), neurovascular interventions, and endovascular therapies, is significantly contributing to market growth. These procedures reduce trauma, shorten hospital stays, and accelerate recovery. Guidewires play a critical role in enabling clinicians to navigate complex vascular structures with precision, improving procedural success and patient outcomes. Expansion of healthcare infrastructure in emerging economies is also creating new opportunities for guidewire deployment.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $1.3 Billion |
| Forecast Value | $2.3 Billion |
| CAGR | 5.7% |
In 2024, the nitinol segment held a 46.3% share 2024. This segment is expected to continue growing due to favorable reimbursement policies and superior material properties, including shape-memory and super-elasticity, which provide enhanced flexibility and kink resistance for navigating tortuous vessels in cardiovascular, peripheral, and neurovascular procedures.
The coated segment held a 89.3% share in 2024. Coated guidewires, using hydrophilic, anti-thrombogenic, hydrophobic, and silicone-based technologies, are preferred for their clinical efficiency and widespread use in interventional procedures.
North America Guidewires Market accounted for a 37.7% share in 2024. The region benefits from advanced healthcare infrastructure, high procedural volumes, rapid adoption of minimally invasive interventions, and continuous technological innovation. High prevalence of cardiovascular diseases, peripheral artery disease, neurovascular conditions, and urological disorders drives demand for guidewires for both diagnostic and therapeutic applications.
Key players operating in the Global Guidewires Market include Boston Scientific, Medtronic, Abbott Laboratories, Cook Medical, Stryker, B. Braun SE, AngioDynamics, Teleflex, Cordis, Olympus, Merit Medical Systems, ASAHI INTECC, Becton Dickinson and Company, and Terumo. Companies in the Global Guidewires Market are strengthening their position by focusing on technological innovation and product differentiation, including the development of smart, coated, and bioresorbable guidewires. Collaborations with hospitals, research centers, and medical device distributors enhance market penetration and clinical adoption. Firms are expanding their footprint in emerging markets by establishing local manufacturing and distribution networks to meet growing procedural demand. Regulatory compliance and securing favorable reimbursement policies also play a vital role in driving sales. Strategic mergers and acquisitions enable companies to consolidate expertise, expand product portfolios, and access advanced R&D capabilities.a